1 hour ago
1 hour ago
Jason Hawkes, MD, MS, discusses emerging biomarkers and clinical characteristics that may help identify patients most likely to benefit from remibrutinib in CSU.
1 hour ago
A review in Wichita, Kansas, shows asthma-related emergency visits spike during storms, underscoring the importance of weather-based asthma action plans for at-risk patients.
1 hour ago
Closing insights on expanding dermatology’s leadership in CSU management and embracing innovation to enhance patient outcomes.
1 hour ago
Jason Hawkes, MD, MS, explains how updated treatment guidelines are incorporating remibrutinib as a key option for CSU after antihistamine failure.